SCHEMBL1997196

SCHEMBL1997196

CCn1nc(C(=O)OC(F)(F)F)c(Cc2ccccc2)c(Nc2cnccc2C)c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.34
PDE4A P27815 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
KDM4C Q9H3R0 5/20 0.34
KDM5A P29375 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 2/20 0.33
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 3/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
DHODH Q02127 1/20 0.32
P2RX7 Q99572 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRA5 P31644 1/20 0.32
KDM4E B2RXH2 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2828120 0.90 KDM4C (0.38) PDE4BPDE4APDE4CPDE4DKDM4C
SCHEMBL1997935 0.85 SMN1; SMN2 (0.35) PDE4BSMN1; SMN2CYP1A2KMT2AL3MBTL1
SCHEMBL2826438 0.84 GPR52 (0.39) KDM4CKDM5AKDM5BPOLBMAPT
SCHEMBL2829346 0.82 KDM4C (0.36) PDE4BPDE4APDE4CPDE4DKDM4C
SCHEMBL2829015 0.80 ALDH1A1 (0.46) KMT2AP2RX7MAPT
SCHEMBL2829340 0.79 KDM4C (0.41) PDE4BPDE4APDE4CPDE4DKDM4C
SCHEMBL2828114 0.79 ROCK2 (0.39) KDM4CKMT2APOLB
SCHEMBL2828108 0.79 KDM4C (0.41) PDE4BPDE4APDE4CPDE4DKDM4C
SCHEMBL2826007 0.79 KDM4C (0.35) PDE4BPDE4APDE4CPDE4DKDM4C
SCHEMBL2828388 0.79 PDE4B (0.39) PDE4BPDE4APDE4CPDE4DKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B PDE4B 3/4885PDE4A 2/4885PDE4C 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.